Q3-osavuosiraportti
Vain PDF
5 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
1 000
Myynti
Määrä
387
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 1 974 | - | - | ||
| 87 | - | - | ||
| 10 | - | - | ||
| 1 859 | - | - |
Ylin
3,78VWAP
Alin
3,46VaihtoMäärä
0,1 26 548
VWAP
Ylin
3,78Alin
3,46VaihtoMäärä
0,1 26 548
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 13.11. | |
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 10.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenIt will be a good Christmas present if a contract is signed by the end of Q4, as the CEO hopes. 43 days remain of Q4 and the selling interest has decreased in the stock, so this could turn out nicely🤩
·13.11. · MuokattuWe were almost at 5kr last time, and back then we didn't know when an agreement would come. Now we are at 3.4kr and an agreement is expected in Q4, the company generates cash and the balance sheet looks very good. The company says that Hitta will start landing contracts, TP remains stable at 50% market share and AZ will continue to look at further indications. The market pricing is completely wrong. And yes, I have increased the position.
·13.11.I see you've been involved with the stock for a while. I'm buying in today, but mostly as a gamble that they get an AZ agreement through, because I find it hard to justify a purchase based on the results of their last 3 Q reports (which I have read fully today). They still incur net losses every quarter, have misreported revenue which has therefore now "fallen" quite a bit. Besides the potential of an agreement with AZ, I also think their increased equity looks good every quarter. So in short: If they didn't get an AZ agreement, would you still invest in them?·14.11. · MuokattuI probably wouldn't focus so much on the equity. They have taken various steps to strengthen it (issuance and conversion of debt to shares). I would rather do a DCF of the company where you include today's operations + a probability-weighted discounting of cash flow from England (DCF+LOA). Already based on today's core operations and growth in Sweden, the company is valued at a discount to future cash flow. If they sign an agreement with AZ and roll out the module within 3 years, I believe the company should be valued well over 20kr. Then there will be further upside if they wish to include other diseases than asthma in the module.
·13.11.So I was right. Q1 is when it's coming! (Hopefully). Based on the report, the probability that 2026 will be the year for Induct just increases. The AZ and UK collaboration is progressing. Wrote off Hitta Bidrag completely in the previous report, but based on the latest events here, it looks like it might work out as well. And the share price we can be at upon agreement will depend heavily on how much AZ will cover, but over 10 is to be expected (given the potential revenues).·13.11.Q4 - agreement, Q1/Q2 - rollout- ·13.11.Imagine 3 years from now: Induct fully rolled out in England and UK. They have added 2-3 further indications and started expansion to other countries. Then we are actually talking about a potential share price of 70-100kr. I expect that they will have to raise money for growth, so diluted a bit lower. The point is, in any case, that the potential is extremely high, and almost ridiculously high. The market doesn't appreciate it yet, but it will come. There is definitely risk, but when you have one of the world's largest pharmaceutical companies on the team, it is an enormous seal of quality.·13.11.As usual, we will totally disagree on the timeline. Doubt it will only take 2-3 years, as a similar process as in the UK with quality assurance must be performed. 5 years, possible.🤞·13.11.The company itself guided 2-3 years in England. After that, they start exploring other countries. So no revenues from other countries, but a signal to the market about further growth beyond England (so that one can price in growth multiples). But we just have to continue to disagree! Then there will be good debates :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
Vain PDF
5 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenIt will be a good Christmas present if a contract is signed by the end of Q4, as the CEO hopes. 43 days remain of Q4 and the selling interest has decreased in the stock, so this could turn out nicely🤩
- ·13.11. · MuokattuWe were almost at 5kr last time, and back then we didn't know when an agreement would come. Now we are at 3.4kr and an agreement is expected in Q4, the company generates cash and the balance sheet looks very good. The company says that Hitta will start landing contracts, TP remains stable at 50% market share and AZ will continue to look at further indications. The market pricing is completely wrong. And yes, I have increased the position.·13.11.I see you've been involved with the stock for a while. I'm buying in today, but mostly as a gamble that they get an AZ agreement through, because I find it hard to justify a purchase based on the results of their last 3 Q reports (which I have read fully today). They still incur net losses every quarter, have misreported revenue which has therefore now "fallen" quite a bit. Besides the potential of an agreement with AZ, I also think their increased equity looks good every quarter. So in short: If they didn't get an AZ agreement, would you still invest in them?·14.11. · MuokattuI probably wouldn't focus so much on the equity. They have taken various steps to strengthen it (issuance and conversion of debt to shares). I would rather do a DCF of the company where you include today's operations + a probability-weighted discounting of cash flow from England (DCF+LOA). Already based on today's core operations and growth in Sweden, the company is valued at a discount to future cash flow. If they sign an agreement with AZ and roll out the module within 3 years, I believe the company should be valued well over 20kr. Then there will be further upside if they wish to include other diseases than asthma in the module.
- ·13.11.So I was right. Q1 is when it's coming! (Hopefully). Based on the report, the probability that 2026 will be the year for Induct just increases. The AZ and UK collaboration is progressing. Wrote off Hitta Bidrag completely in the previous report, but based on the latest events here, it looks like it might work out as well. And the share price we can be at upon agreement will depend heavily on how much AZ will cover, but over 10 is to be expected (given the potential revenues).·13.11.Q4 - agreement, Q1/Q2 - rollout
- ·13.11.Imagine 3 years from now: Induct fully rolled out in England and UK. They have added 2-3 further indications and started expansion to other countries. Then we are actually talking about a potential share price of 70-100kr. I expect that they will have to raise money for growth, so diluted a bit lower. The point is, in any case, that the potential is extremely high, and almost ridiculously high. The market doesn't appreciate it yet, but it will come. There is definitely risk, but when you have one of the world's largest pharmaceutical companies on the team, it is an enormous seal of quality.·13.11.As usual, we will totally disagree on the timeline. Doubt it will only take 2-3 years, as a similar process as in the UK with quality assurance must be performed. 5 years, possible.🤞·13.11.The company itself guided 2-3 years in England. After that, they start exploring other countries. So no revenues from other countries, but a signal to the market about further growth beyond England (so that one can price in growth multiples). But we just have to continue to disagree! Then there will be good debates :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
1 000
Myynti
Määrä
387
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 1 974 | - | - | ||
| 87 | - | - | ||
| 10 | - | - | ||
| 1 859 | - | - |
Ylin
3,78VWAP
Alin
3,46VaihtoMäärä
0,1 26 548
VWAP
Ylin
3,78Alin
3,46VaihtoMäärä
0,1 26 548
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 13.11. | |
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 10.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
Vain PDF
5 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 13.11. | |
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 10.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenIt will be a good Christmas present if a contract is signed by the end of Q4, as the CEO hopes. 43 days remain of Q4 and the selling interest has decreased in the stock, so this could turn out nicely🤩
- ·13.11. · MuokattuWe were almost at 5kr last time, and back then we didn't know when an agreement would come. Now we are at 3.4kr and an agreement is expected in Q4, the company generates cash and the balance sheet looks very good. The company says that Hitta will start landing contracts, TP remains stable at 50% market share and AZ will continue to look at further indications. The market pricing is completely wrong. And yes, I have increased the position.·13.11.I see you've been involved with the stock for a while. I'm buying in today, but mostly as a gamble that they get an AZ agreement through, because I find it hard to justify a purchase based on the results of their last 3 Q reports (which I have read fully today). They still incur net losses every quarter, have misreported revenue which has therefore now "fallen" quite a bit. Besides the potential of an agreement with AZ, I also think their increased equity looks good every quarter. So in short: If they didn't get an AZ agreement, would you still invest in them?·14.11. · MuokattuI probably wouldn't focus so much on the equity. They have taken various steps to strengthen it (issuance and conversion of debt to shares). I would rather do a DCF of the company where you include today's operations + a probability-weighted discounting of cash flow from England (DCF+LOA). Already based on today's core operations and growth in Sweden, the company is valued at a discount to future cash flow. If they sign an agreement with AZ and roll out the module within 3 years, I believe the company should be valued well over 20kr. Then there will be further upside if they wish to include other diseases than asthma in the module.
- ·13.11.So I was right. Q1 is when it's coming! (Hopefully). Based on the report, the probability that 2026 will be the year for Induct just increases. The AZ and UK collaboration is progressing. Wrote off Hitta Bidrag completely in the previous report, but based on the latest events here, it looks like it might work out as well. And the share price we can be at upon agreement will depend heavily on how much AZ will cover, but over 10 is to be expected (given the potential revenues).·13.11.Q4 - agreement, Q1/Q2 - rollout
- ·13.11.Imagine 3 years from now: Induct fully rolled out in England and UK. They have added 2-3 further indications and started expansion to other countries. Then we are actually talking about a potential share price of 70-100kr. I expect that they will have to raise money for growth, so diluted a bit lower. The point is, in any case, that the potential is extremely high, and almost ridiculously high. The market doesn't appreciate it yet, but it will come. There is definitely risk, but when you have one of the world's largest pharmaceutical companies on the team, it is an enormous seal of quality.·13.11.As usual, we will totally disagree on the timeline. Doubt it will only take 2-3 years, as a similar process as in the UK with quality assurance must be performed. 5 years, possible.🤞·13.11.The company itself guided 2-3 years in England. After that, they start exploring other countries. So no revenues from other countries, but a signal to the market about further growth beyond England (so that one can price in growth multiples). But we just have to continue to disagree! Then there will be good debates :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
1 000
Myynti
Määrä
387
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 1 974 | - | - | ||
| 87 | - | - | ||
| 10 | - | - | ||
| 1 859 | - | - |
Ylin
3,78VWAP
Alin
3,46VaihtoMäärä
0,1 26 548
VWAP
Ylin
3,78Alin
3,46VaihtoMäärä
0,1 26 548
Välittäjätilasto
Dataa ei löytynyt